MARKET

CPRX

CPRX

Catalyst Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.770
-0.120
-3.08%
After Hours: 3.800 +0.03 +0.80% 17:59 03/27 EDT
OPEN
3.750
PREV CLOSE
3.890
HIGH
4.000
LOW
3.615
VOLUME
2.39M
TURNOVER
--
52 WEEK HIGH
7.67
52 WEEK LOW
2.232
MARKET CAP
389.85M
P/E (TTM)
12.61
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CPRX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CPRX stock price target is 8.83 with a high estimate of 11.00 and a low estimate of 7.00.

EPS

CPRX News

More
  • Catalyst Pharmaceuticals, Inc. Has 'Anti-Virus' Protection
  • Seeking Alpha - Article · 4d ago
  • 5 Absurdly Cheap Biotech Stocks That Could Make You Filthy Rich
  • MotleyFool.com · 5d ago
  • The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
  • Benzinga · 03/18 11:36
  • Edited Transcript of CPRX earnings conference call or presentation 17-Mar-20 12:30pm GMT
  • Thomson Reuters StreetEvents · 03/18 00:21

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About CPRX

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.
More

Webull offers kinds of Catalyst Pharmaceuticals Inc stock information, including NASDAQ:CPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CPRX stock news, and many more online research tools to help you make informed decisions.